|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM202660028 |
| 003 |
DE-627 |
| 005 |
20250212040838.0 |
| 007 |
tu |
| 008 |
231223s2010 xx ||||| 00| ||chi c |
| 028 |
5 |
2 |
|a pubmed25n0675.xml
|
| 035 |
|
|
|a (DE-627)NLM202660028
|
| 035 |
|
|
|a (NLM)20977840
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Cai, Guang-Xian
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Effect of ultra-micronized Buyang Huanwu decoction on neurological function, quality of life, and serum vascular endothelial growth factor in patients convalescent from cerebral infarction
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.01.2012
|
| 500 |
|
|
|a Date Revised 27.10.2010
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a OBJECTIVE: To study effect of Buyang Huanwu decoction (BYHWD) on neurological function, quality of life, and serum vascular endothelial growth factor (VEGF) in patients convalescent from cerebral infarction, and to evaluate the effect of ultra-micronized BYHWD
|
| 520 |
|
|
|a METHODS: Two hundred and fifty-one patients met the inclusion criteria were randomly assigned to traditional BYHWD (TB) group (n=83), ultra-micronized BYHWD (UB) group (n=85) and the control group (n=83) according to time of entrance into the study with 1:1:1. All patients received rehabilitation training, but for patients in the TB and UB groups, traditional BYHWD (15 g, twice a day) or ultra-micronized BYHWD (5 g, twice a day) was given respectively, for a course of 12 weeks. Clinical curative effect and curative effect of syndrome according to traditional Chinese medicine (TCM) were evaluated. Nerve function and quality of life in patients were evaluated, serum VEGF was determined before and after treatment. The level of VEGF in 23 healthy volunteers was also determined to serve as normal control
|
| 520 |
|
|
|a RESULTS: The total effective rate was 83.5%, 85.5% and 77.1% in UB group, TB group and the control group, respectively, and the total symptomatic effective rate in TCM was 87.0%, 89.2% and 77.1%, respectively. Compared with the control group, there was significant difference in UB or TB group (all P<0.05), but there was no significant difference between UB and TB groups (both P >0.05). Serum VEGF levels (ng/L) were significantly lower before treatment in control group, TB group and UB group than those in normal control group (79.87±2.81, 80.19±3.23, 80.23±3.18 vs. 68.13±3.39, all P<0.05). Neurologic deficit score (NDS), quality of life and serum VEGF were improved after treatment in three groups, but they were better in UB or TB group than the control group [NDS: 11.95±5.03, 12.68±4.67 vs. 15.23±5.12, quality of life score: 64.71±6.73, 63.56±6.53 vs. 59.09±6.81, serum VEGF (ng/L): 76.38±3.02, 76.84±3.18 vs. 70.26±3.15 , all P<0.05], but there was no significant difference between UB and TB groups (all P >0.05)
|
| 520 |
|
|
|a CONCLUSION: BYHWD can improve neurological function and quality of life, and increase serum VEGF in patients convalescent from cerebral infarction, and ultra-micronized BYHWD, the dosage can be decreased
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Drugs, Chinese Herbal
|2 NLM
|
| 650 |
|
7 |
|a Vascular Endothelial Growth Factor A
|2 NLM
|
| 650 |
|
7 |
|a buyang huanwu
|2 NLM
|
| 700 |
1 |
|
|a Liu, Bai-Yan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
|d 1998
|g 22(2010), 10 vom: 26. Okt., Seite 591-4
|w (DE-627)NLM098227793
|x 1003-0603
|7 nnns
|
| 773 |
1 |
8 |
|g volume:22
|g year:2010
|g number:10
|g day:26
|g month:10
|g pages:591-4
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 22
|j 2010
|e 10
|b 26
|c 10
|h 591-4
|